[The use of nebivolol in menopausal women with hypertension].
Nebivolol was given for 8 weeks to 34 menopausal women with grade 1 and 2 hypertension. Monotherapy was effective in 66,7% of patients, while in other patients combination with hydrochlorothiazide (12.5 mg) was required. The use of nebivolol was associated with decreased rate and severity of vasomotion reactions and thus with positive effect on menopausal syndrome. Nebivolol appeared to be safe and metabolically neutral.
Cardiology Center for South-Western Administrative Region of Moscow, Russia.
N P
NP
Alekseeva
E V
EV
Belova
V G
VG
Larin
F Iu
FIu
Akhundov
G F
GF
Krasina
L V
LV
Kotliarova
D000367:Age Factors; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001578:Benzopyrans / Q000008:administration & dosage / Q000627:therapeutic use*; D004232:Diuretics; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D008593:Menopause; D008875:Middle Aged; D000068577:Nebivolol; D017698:Postmenopause; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
D000959:Antihypertensive Agents; D001578:Benzopyrans; D004232:Diuretics; D004983:Ethanolamines; D049993:Sodium Chloride Symporter Inhibitors; D000068577:Nebivolol; D006852:Hydrochlorothiazide